Beranda › Kanker Payudara Triple-Negatif › North Carolina
Uji klinis Kanker Payudara Triple-Negatif di North Carolina
21 studi untuk Kanker Payudara Triple-Negatif mencari peserta di lokasi di North Carolina.
Kota di North Carolina
Teks studi resmi (Bahasa Inggris)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Carolina Cancer Research Center, Wilson
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06270706The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
Menerima peserta
Usia 30 ke atas · Wanita · Diperbarui 25 Sep 2026 · NCT02945579Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Levine Cancer Institute ( Site 0083), Charlotte
- Cape Fear Valley Health System ( Site 0136), Fayetteville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06393374Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT07340541Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Wake Forest University at Clemmons, Clemmons
- Wake Forest University Health Sciences, Winston-Salem
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT03606967Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Lineberger Comprehensive Cancer Center, Chapel Hill
- Novant Health Cancer Institute - Elizabeth (Breast), Charlotte
- Duke Cancer Institute, Durham
- dan 2 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT05633654Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Duke University, Durham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT05846789Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
- Wake Forest Baptist Health Sciences, Winston-Salem
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT04677816A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Duke Cancer Institute, Durham
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT06926868DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Duke University Medical Center, Durham
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06176261A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07749586Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
- University of North Carolina, Chapel Hill
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT06347068Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Duke Cancer Institute /ID# 276267, Durham
- Carolina BioOncology Institute /ID# 232597, Huntersville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT05005403Study of XB010 in Subjects With Solid Tumors
- Carolina BioOncology Institute, Huntersville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT06545331I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT01042379Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- The University of North Carolina at Chapel Hill, Chapel Hill
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Apr 2026 · NCT04468061Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
- University of North Carolina, Chapel Hill
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Apr 2026 · NCT07276880PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Apr 2026 · NCT07069595A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Huntersville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jan 2026 · NCT06999187A Study of NX-1607 in Adults With Advanced Malignancies
- University of North Carolina, Chapel Hill
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2025 · NCT05107674Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.